Ledyard National Bank’s Alexion Pharmaceuticals ALXN Stock Holding History

Ledyard National Bank’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-419	Closed	-$59K	–	841
2017 Q3	$59K	Buy	419 +19	+5%	+$2.58K	0.01%	428
2017 Q2	$49K	Hold	400	–	–	0.01%	411
2017 Q1	$48K	Hold	400	–	–	0.01%	416
2016 Q4	$49K	Hold	400	–	–	0.01%	318
2016 Q3	$49K	Hold	400	–	–	0.01%	321
2016 Q2	$47K	Hold	400	–	–	0.01%	308
2016 Q1	$56K	Hold	400	–	–	0.01%	310
2015 Q4	$76K	Hold	400	–	–	0.01%	270
2015 Q3	$63K	Hold	400	–	–	0.01%	280
2015 Q2	$72K	Hold	400	–	–	0.01%	267
2015 Q1	$69K	Hold	400	–	–	0.01%	260
2014 Q4	$74K	Hold	400	–	–	0.01%	251
2014 Q3	$66K	Hold	400	–	–	0.01%	240
2014 Q2	$63K	Hold	400	–	–	0.01%	249
2014 Q1	$61K	Hold	400	–	–	0.01%	244
2013 Q4	$53K	Hold	400	–	–	0.01%	258
2013 Q3	$46K	Hold	400	–	–	0.01%	237
2013 Q2	$37K	Buy	+400	New	+$38.5K	0.01%	241

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Ledyard National Bank's ALXN Position: Q4 2017 in Review

Ledyard National Bank sold out of Alexion Pharmaceuticals (ALXN) in Q4 2017, closing a stake of 419 shares — an estimated $59K sold.

Ledyard National Bank first reported a position in ALXN in Q2 2013 and held it in 18 quarters. The position peaked at $76K in Q4 2015. 587 funds tracked by Wall St. Rank hold ALXN as of Q4 2017.

Ledyard National Bank reported no remaining Alexion Pharmaceuticals position as of Q4 2017 after selling out during the quarter.
Ledyard National Bank sold 419 Alexion Pharmaceuticals shares in Q4 2017, an estimated $59K.
Ledyard National Bank first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 18 quarters.
Ledyard National Bank's Alexion Pharmaceuticals position peaked at $76K in Q4 2015.
587 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2017.

Based on Ledyard National Bank's 13F filing for Q4 2017, filed 30 Jan 2018.